Compare NUVL & CPRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUVL | CPRI |
|---|---|---|
| Founded | 2017 | 1981 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Apparel |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 3.2B |
| IPO Year | 2021 | 2011 |
| Metric | NUVL | CPRI |
|---|---|---|
| Price | $103.86 | $25.15 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 11 |
| Target Price | ★ $135.00 | $26.55 |
| AVG Volume (30 Days) | 638.5K | ★ 2.9M |
| Earning Date | 10-30-2025 | 02-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,369,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.99 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $55.54 | $11.86 |
| 52 Week High | $112.88 | $28.27 |
| Indicator | NUVL | CPRI |
|---|---|---|
| Relative Strength Index (RSI) | 51.36 | 52.76 |
| Support Level | $100.42 | $25.05 |
| Resistance Level | $107.99 | $27.00 |
| Average True Range (ATR) | 3.02 | 0.91 |
| MACD | -1.07 | -0.27 |
| Stochastic Oscillator | 29.85 | 3.98 |
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
Capri Holdings is a marketer, distributor, and retailer of upscale accessories and apparel in the Americas, Europe, and Asia. Michael Kors, Capri's original and largest brand by sales, offers handbags, footwear, and apparel through more than 700 company-owned stores, wholesale, and e-commerce. Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. Its products are sold in more than 200 company-operated stores. Capri also owns a third brand, Versace, but has agreed to sell it to Prada. John Idol has served as Capri's CEO since 2003.